Koyfin Home > Directory > Health Care > Adamas Pharma > EBITDA Margin

Adamas Pharma EBITDA Margin Chart (ADMS)

Adamas Pharma annual/quarterly EBITDA Margin from 2012 to 2020. An EBITDA margin is a measurement of a company's earnings before interest, taxes, depreciation, and amortization as a percentage of its total revenue.
  • Adamas Pharma EBITDA Margin for the quarter ending June 06, 2020 was $-38m a -283.40% increase of 107m year over year
  • Adamas Pharma EBITDA Margin for the last 12 months ending June 06, 2020 was $-96m a -86.50% increase of 83m year over year
  • Adamas Pharma Annual EBITDA Margin for 2019 was $-163m a -104.49% increase of 170m from 2018
  • Adamas Pharma Annual EBITDA Margin for 2018 was $-334m a -4,455.52% increase of 14,862m from 2017
  • Adamas Pharma Annual EBITDA Margin for 2017 was $-15,195m a 30.77% decrease of -4,675m from 2016
Other Margins & Efficiency Metrics:
  • Adamas Pharma Return on Capital % for the quarter ending September 09, 2018 was -29.66 a -68.05% increase of 20.18 year over year
  • Adamas Pharma Return on Equity % for the quarter ending September 09, 2018 was -103.21 a -49.69% increase of 51.29 year over year
View Chart On Koyfin

Quarterly ADMS EBITDA Margin Data

06/2020$-38m
03/2020$-89m
12/2019$-130m
09/2019$-145m
06/2019$-169m
03/2019$-225m
12/2018$-187m
09/2018$-267m
06/2018$-392m
03/2018$-1,200m

Annual ADMS EBITDA Margin Data

2019$-163m
2018$-334m
2017$-15,195m
2016$-10,520m
2015$-2,975m
2014$33m
2013$80m
2012$53m
2011$-403m